Tsumura & Co
TSE:4540
Tsumura & Co
Treasury Stock
Tsumura & Co
Treasury Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Treasury Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tsumura & Co
TSE:4540
|
Treasury Stock
-¥2.3B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-20%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Treasury Stock
-¥24.8B
|
CAGR 3-Years
35%
|
CAGR 5-Years
22%
|
CAGR 10-Years
-3%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Treasury Stock
-¥147.3B
|
CAGR 3-Years
-58%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-26%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Treasury Stock
-¥67.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Treasury Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Astellas Pharma Inc
TSE:4503
|
Treasury Stock
-¥37.5B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
8%
|
|
Tsumura & Co
Glance View
Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.
See Also
What is Tsumura & Co's Treasury Stock?
Treasury Stock
-2.3B
JPY
Based on the financial report for Dec 31, 2024, Tsumura & Co's Treasury Stock amounts to -2.3B JPY.
What is Tsumura & Co's Treasury Stock growth rate?
Treasury Stock CAGR 10Y
-20%
Over the last year, the Treasury Stock growth was 2%. The average annual Treasury Stock growth rates for Tsumura & Co have been -51% over the past three years , -28% over the past five years , and -20% over the past ten years .
You don't have any saved screeners yet